Main content

    Renal and Urinary Tract Cancer Clinical Trials

    CPMC Cancer ServicesOpens new window

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab Versus Placebo in Subjects With High Risk Invasive Urothelial Carcinoma (CheckMate 274: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 274)
    Description: The purpose of this study is to determine the efficacy and safety of nivolumab versus placebo in participants who have undergone radical surgery for invasive urothelial cancer
    Investigator: Ari Baron, MD
    Eligibility: Subjects 18 y/o and older with invasive urothelial cancer at high risk of recurrence originating in the bladder, ureter, or renal pelvis; must have had radical surgical resection (e.g. radical cystectomy), performed within the last 90 days; must have disease free status as determined by imaging within 4 weeks of dosing
    Status: Active and open to enrollment
    Contact: Madeline Decker, 415-600-3613, Email: GasperP@cpmcri.org about Study BMS CA209-274

    Title: A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma
    Description: This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have have high grade upper tract urothelial carcinoma proven by one of the following: Biopsy; Urinary cytology with a 3-dimensional upper urinary tract mass on cross-sectional imaging; or Urinary cytology and a mass visualized during upper urinary tract endoscopy
    Status: Please contact site for study status
    Contact: Madeline Decker, 415-600-3613, Email: DeckerM@cpmcri.org about Study EA8141

    Title: A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
    Description: This randomized phase II trial studies how well cabozantinib-s-malate, crizotinib, volitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body.
    Investigators: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, who have histologically or cytologically confirmed papillary histology renal cell carcinoma which is metastatic or locally advanced disease not amenable to surgical resection
    Status: Please contact site for study status
    Contact: Joni Beemsterboer, 415-600-3967, Email: BeemstJ@cpmcri.org about Study SWOG S1500

    • updated December 2016

    Back to top